INOVIO PHARMACEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
INO$1.51+24.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| For the Year ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenues: | ||
| Revenue from collaborative arrangement | $65,343 | $217,756 |
| Operating expenses: | ||
| Research and development | 54,206,874 | 75,620,340 |
| General and administrative | 32,680,573 | 36,996,338 |
| Total operating expenses | 86,887,447 | 112,616,678 |
| Loss from operations | (86,822,104) | (112,398,922) |
| Other income (expense): | ||
| Interest income | 2,420,160 | 4,766,993 |
| Interest expense | — | (177,833) |
| Change in fair value of common stock warrant liabilities | 493,231 | 2,808,608 |
| Gain (loss) on investment in affiliated entity | 489,844 | (1,166,443) |
| Net unrealized gain on available-for-sale equity securities | 1,114,781 | 2,077,182 |
| Other expense, net | (2,641,813) | (3,163,711) |
| Net loss | $(84,945,901) | $(107,254,126) |
| Net loss per share | ||
| Basic and diluted | $(1.81) | $(3.95) |
| Weighted average number of common shares used to compute net loss per share | ||
| Basic and diluted | 46,886,413 | 27,160,863 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.